Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

402 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-16

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma(HCC) is prevalent in the hepatitis B virus(HBV) infection endemic areas. For early stage of HCC, surgical resection, radiofrequency ablation (RFA) or microwave ablation (MWA) are the main treatment options. However, the risk of recurrence is as high as 50% in 5 years by surgical resection or 60-70% in 5 years by RFA. In average, the recurrence rate of HCC at 2 years is 30%. Many factors are associated with the HCC recurrence, including HBV viral load, cirrhotic stage, tumor size, tumor number, vascular invasion, alpha-fetoprotein(AFP) level and so on. Of them, high HBV viral load is associated with the risk of HCC recurrence after surgical resection, especially on late recurrence. In one previous randomized controlled trial, patients who received lamivudine, adefovir dipivoxil, or entecavir had significantly decreased early recurrence of HCC, however, whether nucleos(t)ide analogues(NUCs) can further reduce the risk of recurrence in patients with low viral loads (\<2000 IU/ml) is still unclear.

In EASL 2017 guideline, all patients with compensated or decompensated cirrhosis need antiviral treatment, with any detectable HBV DNA level and regardless of alanine aminotransferase(ALT) levels. In Taiwan, even in chronic hepatitis B(CHB) infection patients with HCC, NUC is not reimbursed if their HBV viral load was less than 2000 IU/ml. It is an important unmet medical need to understanding the role of TAF in reducing the risk of recurrence in HBV-HCC patients with low HBV viral load (HBV DNA\<2000 IU/ml) and significant liver fibrosis after curative treatment (The definition of significant liver fibrosis was based on reference. In our recent retrospective study, the risk of recurrence and survival are comparable between patients with and without NUCs treatment before HCC development only if NUCs treatment can be provided after curative treatment of HCC. However, a higher risk of recurrence was observed in cirrhotic patients with prior NUCs treatment before HCC occurrence. It would be interesting to investigate the incidence of recurrence by switching to tenofovir alafenamide(TAF) after curative treatment of HCC in patients already on NUCs treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

NCT01872988

Chronic Hepatitis B Hepatocellular Carcinoma

TERMINATED PHASE3

Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load

NCT02308319

Carcinoma, Hepatocellular

UNKNOWN PHASE4

DAA in the Risk of Recurrence After Curative Treatment of HCC

NCT02959359

Hepatocellular Carcinoma

WITHDRAWN PHASE4

TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)

NCT00960518

Hepatitis B Virus Hepatocellular Carcinoma

UNKNOWN PHASE2

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

NCT04392700

Hepatocellular Carcinoma Recurrent

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HCC Patients After Curative Treatment With Low HBV Viral Load

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Part 1: NUC-naïve patients will be randomization into tenofovir alafenamide(TAF) or placebo arm in 1:1 ratio.

Part 2: NUCs-treated patients will be switched to tenofovir alafenamide(TAF) treatment.

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.

Group Type EXPERIMENTAL

Vemlidy® (Tenofovir Alafenamide; TAF)

Intervention Type DRUG

Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).

Arm 2

NUC-naïve patients will be randomization into placebo arm.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).

Arm 3

NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.

Group Type ACTIVE_COMPARATOR

Vemlidy® (Tenofovir Alafenamide; TAF)

Intervention Type DRUG

Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vemlidy® (Tenofovir Alafenamide; TAF)

Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).

Intervention Type DRUG

Placebo

Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HBsAg-positive for more than 6 months.
* HCC after curative treatment (eight by surgical resection or RFA or MWA) with significant liver fibrosis (either by Ishak≧2, Metavir≧2, Knodell≧3) or cirrhosis and HBV DNA\<2,000 IU/ml.
* The duration of curative treatment of HCC to study enrollment should be less than 90 days.
* Curative treatment is confirmed by contrast-enhanced CT or MR after the surgery/RFA/MWA.